Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
As of December 31, 2021, the number of shares outstanding of our Common Stock was:
719,023,254
Outstanding Shares
754,973,254
02/02/2022
zero dilution....launch pad!
Moderna obtained a priority review voucher (PRV) when received the full approval of its Covid vaccine from FDA. The vouchers can be used for a priority review of a new drug, offering a short cut to an FDA decision, or can be sold on the open market — for upwards of $100 million.
I am sure Moderna will keep it for its new drugs.
.10 up
$BLLB zero dilution:
Outstanding Shares
754,973,254
02/02/2022
Restricted
77,217,818
02/02/2022
Float
648,878,353
02/02/2022
Cash Deal For Africa's Innovative MRNA Vaccine:
Cape Town-based Afrigen Biologics and Vaccines is leading a pilot project, backed by the World Health Organization and the COVAX initiative, to tweak Moderna's shot.
https://www.barrons.com/news/cash-deal-for-africa-s-innovative-mrna-vaccine-01643906107
$MRNA big company!
other news:
We will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 24, 2022 to report our fourth quarter and full year 2021 financial results, along with a corporate update. Find out more at
https://investors.modernatx.com/news/news-details/2022/Moderna-to-Report-Fourth-Quarter-and-Full-Year-2021-Financial-Results-on-Thursday-February-24-2022/default.aspx
big company!
runner!
VWIGX - Vanguard International Growth Fund Investor Shares reports 7.17% increase in ownership of MRNA / Moderna Inc
2022-01-31 - VWIGX - Vanguard International Growth Fund Investor Shares has filed a NPORT-P form disclosing ownership of 10,028,109 shares of Moderna Inc (RU:MRNA) with total holdings valued at $3,534,206,454 USD as of 2021-11-30. VWIGX - Vanguard International Growth Fund Investor Shares had filed a previous NPORT-P on 2021-10-29 disclosing 9,357,573 shares of Moderna Inc at a value of $3,524,904,173 USD. This represents a change in shares of 7.17 percent and a change in value of 0.26 percent during the quarter.
https://fintel.io/so/ru/mrna/vanguard-world-fund-vanguard-international-growth-fund-investor-shares
multibagger$$$$$$$$ big news imminent
nice $PALI
$bllb Caveat removed! Updates coming in February. Management is committed to creating real, sustained value for $BLLB shareholders. Stay tuned.
Float:648,878,353
Updates coming in February. Management is committed to creating real, sustained value for $BLLB shareholders. Stay tuned.
— Bell Buckle Holdings (@bell_buckle) February 1, 2022
$bllb Caveat removed! Updates coming in February. Management is committed to creating real, sustained value for $BLLB shareholders. Stay tuned.
Updates coming in February. Management is committed to creating real, sustained value for $BLLB shareholders. Stay tuned.
— Bell Buckle Holdings (@bell_buckle) February 1, 2022
8th human trial for HIV vaccine. Great article summarizing trials and progress. Moderna strong.
George Washington University, one of the sites where the trial is taking place, described it as the first human trial of a mRNA-based HIV vaccine.
https://www.washingtonpost.com/health/2022/02/01/moderna-vaccine-mrna-hiv-trial/
Unvaccinated people are at more risk of catching BA.2, the new Omicron lineage, than any prior type of COVID-19, Danish data indicates
https://www.yahoo.com/news/unvaccinated-people-more-risk-catching-144808623.html
Oh yeah, I forgot to mention that Moderna vacciness are more effective than pfizer's, imagine that from a company that is 1/15th the age of pfe and that did not exist 12 years ago.
Updates coming in February. Management is committed to creating real, sustained value for $BLLB shareholders. Stay tuned.
— Bell Buckle Holdings (@bell_buckle) February 1, 2022
this is just the beginning of something very interesting.
Moderna's COVID-19 Vaccine Receives Full Approval From FDA in US
This is the biggest news we long investors have been waiting for and finally the first US approved Moderna commercial product is in the market.
MODERNA RECEIVES FULL U.S. FDA APPROVAL FOR COVID-19 VACCINE SPIKEVAX
https://investors.modernatx.com/news/news-details/2022/Moderna-Receives-Full-U.S.-FDA-Approval-for-COVID-19-Vaccine-Spikevax/default.aspx
Moderna also has plenty of cash. Wall Street analysts estimate that the company will have $27.4 billion by the end of this year, according to FactSet. That enormous bankroll constitutes the best case for Moderna. With that cash, it can bulk itself up quickly enough to compete on a level with Pfizer and Sanofi,,,,,,
10 Signs Your Stock is Being Manipulated:
https://www.griproom.com/fun/10-signs-your-stock-is-being-manipulated
It's a great read to that bit!
You can spend weeks analyzing financials, company management, and growth prospects, determine a business is fantastic, only to watch it slowly disintegrate.
Your stock just keeps dropping.
And dropping.
And eventually you sell.
A year later you check in on the stock and see that it’s doubled, tripled, or gone parabolic.
This isn’t bad luck. Wall Street manipulated your stock and stole your shares.
They know you check the price every day. They know you get angry when you see it dropping for no reason.
Two years ago, no one outside of biotech had heard of Moderna. Now, it is the most famous biotech in history!
https://www.reportdoor.com/moderna-faces-challenges-beyond-the-covid-vaccine-its-stock-is-still-a-buy-for-the-long-term/
A Big Investor Bought Up Moderna ,Royal London Asset Management significantly raised its investments in Moderna
https://newsfilter.io/a/75b85f018723e83f467eb10c70d014bc
Covid isn’t going anywhere! The latest Covid variant is 1.5 times more contagious than omicron and already circulating in almost half of U.S. states
https://www.cnbc.com/2022/01/28/the-new-bapoint2-omicron-subvariant-is-already-circulating-in-half-of-us-states.html
Moderna Faces Challenges Beyond the Covid Vaccine. Its Stock Is Still a Buy.
https://www.barrons.com/articles/buy-moderna-stock-long-term-covid-vaccine-51643383455
Say goodbye to $150,Now it makes sense why they were scrambling to sell those 150 puts yesterday,,,,, anything can happen!
Moderna's Chief Medical Officer provides perspective on pandemic progress and outlook: "Interesting"
https://finance.yahoo.com/video/modernas-chief-medical-officer-provides-184327543.html
HIV vaccine an unmet need being addressed using mRNA. Another bun in the oven!
Moderna and IAVI Launch Trial of HIV Vaccine Antigens Delivered Through mRNA Technology
news out- vaccine HIV: Phase 1 trial aims to build on response seen in proof-of-concept trial
CAMBRIDGE, MA and NEW YORK, NY / ACCESSWIRE / January 27, 2022 / IAVI, the nonprofit scientific research organization, and biotechnology company Moderna announced today that first doses have been administered in a clinical trial of experimental HIV vaccine antigens at George Washington University (GWU) School of Medicine and Health Sciences in Washington, D.C.
The Phase 1 trial, IAVI G002, is designed to test the hypothesis that sequential administration of priming and boosting HIV immunogens delivered by messenger RNA (mRNA) can induce specific classes of B-cell responses and guide their early maturation toward broadly neutralizing antibody (bnAb) development. The induction of bnAbs is widely considered to be a goal of HIV vaccination, and this is the first step in that process. The immunogens being tested in IAVI G002 were developed by scientific teams at IAVI and Scripps Research and will be delivered via Moderna's mRNA technology
"We are tremendously excited to be advancing this new direction in HIV vaccine design with Moderna's mRNA platform. The search for an HIV vaccine has been long and challenging, and having new tools in terms of immunogens and platforms could be the key to making rapid progress toward an urgently needed, effective HIV vaccine," says Mark Feinberg, M.D., Ph.D., president and CEO of IAVI. "We are grateful to all of our partners and especially to the Bill & Melinda Gates Foundation for funding this trial."
"We are very pleased to be partnering with IAVI and the Bill & Melinda Gates Foundation to apply our mRNA technology in the setting of HIV. At Moderna, we believe that mRNA offers a unique opportunity to address critical unmet public health needs around the world," said Stephen Hoge, M.D., President of Moderna. "We believe advancing this HIV vaccine program in partnership with IAVI and Scripps Research is an important step in our mission to deliver on the potential for mRNA to improve human health."
The HIV vaccine antigens being evaluated as mRNA in this study were originally developed as proteins by William Schief, Ph.D., professor at Scripps Research and executive director of vaccine design at IAVI's Neutralizing Antibody Center (NAC), and colleagues. In 2021, Dr. Schief announced results from the IAVI G001 clinical trial, showing that an adjuvanted protein-based version of the priming immunogen (eOD-GT8 60mer) induced the desired B-cell response in 97% of recipients. IAVI G002 not only tests priming of the desired immune response using mRNA delivery of eOD-GT8 60mer, but also assesses the ability of a boosting immunogen to induce further maturation of B cells. Given the speed with which mRNA vaccines can be produced, this platform offers a more nimble and responsive approach to vaccine design and testing, potentially shaving off years from typical vaccine development timelines.
The Schief lab has been a pioneer of the vaccine design approach known as germline targeting. Naive B cells display antibodies encoded by unmutated, or "germline" genes. A series of vaccines, which would begin with the prime-boost immunogens tested here, may be able to target specific naive B cells and induce them to mature into bnAb-producing ones. In the lab, bnAbs have been shown to neutralize a broad range of HIV variants, and one bnAb, VRC01, was recently shown to be capable of protecting humans against infection by neutralization-susceptible HIV strains. VRC01 is a member of the class of bnAbs targeted in IAVI G001.
"We've seen promising proof of concept for germline targeting in IAVI G001, and this trial lets us take that approach to the next stage. What's more, we've been able to expedite production of clinical trial material at a remarkably rapid pace because of Moderna's technology," said Schief.
Years of work in a long-standing NAC partnership between IAVI and Scripps Research have enabled the development of these vaccine antigens. The organizations will continue to collaborate as they extend and evaluate the sequence of promising immunogens to elicit bnAbs.
IAVI G002 is sponsored by IAVI and takes place at four sites: GWU School of Medicine and Health Sciences (lead investigator David Diemert, M.D.), Hope Clinic of Emory Vaccine Center in Atlanta (lead investigator Srilatha Edupuganti, M.D.), Fred Hutchinson Cancer Research Center (Fred Hutch) in Seattle (lead investigator Julie McElrath, M.D., Ph.D.), and the University of Texas-Health Science Center at San Antonio (lead investigator Barbara Taylor, M.D., M.S.). The sites will enroll 56 healthy, HIV-negative adult volunteers. Forty-eight participants will receive one or two doses of eOD-GT8 60mer mRNA Vaccine (mRNA-1644), with 32 of them receiving the boost Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core). An additional eight volunteers will receive the boost immunogen alone. Participants will be monitored for safety for six months after last vaccination. Participants' immune responses to the vaccine candidates will be examined in molecular detail to evaluate whether the targeted responses were achieved.
Diemert said, "We at GWU School of Medicine and Health Sciences are pleased to be part of this endeavor that aims to induce the next step of B-cell maturation toward the goal of generating antibodies that can neutralize a broad range of HIV variants. Further immunogens will be needed to guide the immune system on this path, but this prime-boost combination could be the first key element of an eventual HIV immunization regimen."
The Collaboration for AIDS Vaccine Discovery (CAVD) Comprehensive Cellular Vaccine Immune Monitoring Consortium/the Dale and Betty Bumpers Vaccine Research Center at the National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH), the CAVD Comprehensive Antibody Vaccine Immune Monitoring Consortium, Duke University's Human Vaccine Institute, Fred Hutch, and the Karolinska Institute will be performing key analytical assays in support of the trial, to assess whether the targeted immune response is elicited. The CAVD Vaccine Immunology Statistical Center played an important role contributing to the study design, analytical methods development, and data evaluation. In January 2016, Moderna entered a global health project framework agreement with the Bill & Melinda Gates Foundation to advance mRNA-based development projects for various infectious diseases.
IAVI and Scripps Research developed the eOD-GT8 60mer and Core-g28v2 60mer mRNA candidates with support from the Bill & Melinda Gates Foundation, the Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID) at NIAID at the NIH, and Moderna.
Research at the IAVI NAC that contributed to the development of the vaccine candidates was also made possible by the government of the Netherlands through the Ministry of Foreign Trade & Development Cooperation and through the generous support of the American people through the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) through the United States Agency for International Development (USAID). The contents are the responsibility of IAVI and Moderna and do not necessarily reflect the views of USAID or the United States government.
About IAVI
IAVI is a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges including HIV, tuberculosis, and emerging infectious diseases. Its mission is to translate scientific discoveries into affordable, globally accessible public health solutions. Read more at iavi.org.
About Moderna
In 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.
Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.
Warren Buffett’s advice for a volatile market: patience pays!
This is what matters!
with the amount of time it took to get rid of the CE and now pink current, one might assume during that long stretch Kim has had plenty of time to look for merger candidates, I can't imagine we are too far off from an announcement!!!!!!!
Shorts, prepare to pay the piper starting today!!!! maybe
It's only the beginning!
now we're back in gear. Should be some good momentum over the next few days as it becomes clear that omicron is just the beginning of new variants and as shorts cover.
Harvard: No Omicron immunity without booster, study finds:
https://news.harvard.edu/gazette/story/2022/01/no-omicron-immunity-without-booster-study-finds/
The #1 institutional holder Baillie Gifford has increased its holding by 8.42% to 45,772,079 shares:
https://www.nasdaq.com/market-activity/stocks/mrna/institutional-holdings
MODERNA ANNOUNCES FIRST PARTICIPANT DOSED IN PHASE 2 STUDY OF OMICRON-SPECIFIC BOOSTER CANDIDATE AND PUBLICATION OF DATA ON BOOSTER DURABILITY AGAINST OMICRON VARIANT
https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-First-Participant-Dosed-in-Phase-2-Study-of-Omicron-Specific-Booster-Candidate-and-Publication-of-Data-on-Booster-Durability-Against-Omicron-Variant/default.aspx
Parabolic reflector$$$$
A two-dose regimen of 100 µg mRNA-1273 vaccine in adolescents and of 50 µg in children elicited neutralization responses against the Omicron variant that were reduced compared with the wild-type D614G, and numerically higher than those in adults.
https://www.medrxiv.org/content/10.1101/2022.01.24.22269666v1
$BLLB alert Caveat removed!